High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels:: Molecular predictors for survival of stage 2 soft tissue sarcoma patients

被引:0
|
作者
Köhler, T
Würl, P
Meye, A
Lautenschläger, C
Bartel, F
Borchert, S
Bache, M
Schmidt, H
Holzhausen, HJ
Taubert, H
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle An Der Saale, Germany
[2] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[3] Univ Leipzig, Clin Surg 1, Leipzig, Germany
[4] Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle An Der Saale, Germany
[5] Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle An Der Saale, Germany
[6] Univ Dresden, Urol Clin, Dresden, Germany
关键词
soft tissue sarcoma; prognostic markers; bad; bax; bcl-xL bcl-2; mRNA expression; quantitative; high-throughput RT-PCR; 5 ' nuclease assay; DNA-coated strips;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the bcl-2 gene family members in promoting or antagonizing apoptosis in malignant tumors, including soft tissue sarcomas (STS), is well known. However, the impact of mRNA expression of bcl-2 family genes on prognosis has not been thoroughly investigated in STS. Samples from 82 STS patients were analyzed for mRNA expression of bad, bax, bcl-x(L) and bcl-2 by a high-throughput quantitative RTPCR approach, using validated assays based on TaqMan(R) technology. The mRNA data, related to glyceraldehyde-3-phosphate dehydrogenase expression measured in the same sample, were analysed for their correlation to tumor stage and overall survival of patients. In a Kaplan-Meier analysis none of the mRNA levels investigated differed significantly with regard to their impact on survival (log-rank test). However, after including the tumor stage in the statistical analysis, a borderline significance was observed for bad mRNA expression (p=0.068) indicating a stage-specific impact of mRNA expression on prognosis. Considering STS patients of tumor stage 2, multivariate Cox analysis revealed that bad mRNA values greater than or equal to10 (p=0.0039; RR=9.08), bcl-x(L) greater than or equal to1.5 (p=0.067; RR = 4.59), bax greater than or equal to0.005 (p=0.1; RR=2.84) and bcl-2 <3 (p=0.42; RR=1.7) were associated with a poor prognosis. Combined high bad/bcl-x(L) mRNA expression levels revealed a 20 fold increase in the relative risk of tumor-related death (p=0.016) when comparing the poor and good prognosis groups. There was a 14.5 fold and 6.5-fold increase in the risk for the combinations of high bax/bcl-x(L) mRNA (p=0.018) and bax/bcl-2 mRNA expression (p=0.017), respectively. In conclusion, high bad mRNA levels and combined values of bad/bcl-x(L), bax/bcl-x(L) and bax/bcl-2 appear to be independent prognostic factors at least for stage 2 STS patients. In the combinations of mRNA levels there was more than an additive effect pointing to different pathways of prognostic relevance.
引用
收藏
页码:1553 / 1559
页数:7
相关论文
共 50 条
  • [21] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels
    G Tudor
    A Aguilera
    D O Halverson
    N D Laing
    E A Sausville
    Cell Death & Differentiation, 2000, 7 : 574 - 586
  • [22] BCL-2 AND BCL-XL: POTENTIAL TARGETS FOR INHIBITION BY siRNA
    Yakobson, E.
    Vestin, A.
    Weinstein, J.
    Sergeyev, V.
    Mandel, M.
    Khazanov, E.
    Barenholz, Y.
    Agami, R.
    Bank, I.
    Sidi, Y.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3634 - 3634
  • [23] Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
    Westhoff, Mike-Andrew
    Schuler-Ortoli, Marie
    Zerrinius, Daniela
    Hadzalic, Amina
    Schuster, Andrea
    Strobel, Hannah
    Scheuerle, Angelika
    Wong, Tiana
    Wirtz, Christian Rainer
    Debatin, Klaus-Michael
    Peraud, Aurelia
    PHARMACEUTICALS, 2022, 15 (01)
  • [24] Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
    Daver, Naval
    Konopleva, Marina
    BLOOD, 2016, 128 (10) : 1316 - 1317
  • [25] Unknotting the roles of Bcl-2 and Bcl-xL in cell death
    Kim, R
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) : 336 - 343
  • [26] Expression level of plasma Bcl-xL and Bcl-2 in patients with systemic lupus erythematosus
    Tao, Sha-Sha
    Lu, Man-Man
    Leng, Rui-Xue
    Pan, Hai-Feng
    Ye, Dong-Qing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6801 - 6806
  • [27] Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma
    Leiter, U
    Schmid, RM
    Kaskel, P
    Peter, RU
    Krähn, G
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2000, 292 (05) : 225 - 232
  • [28] Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma
    U. Leiter
    R. M. Schmid
    P. Kaskel
    R. U. Peter
    G. Krähn
    Archives of Dermatological Research, 2000, 292 : 225 - 232
  • [29] A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
    Aguilar, Angelo
    Zhou, Haibin
    Chen, Jianfang
    Liu, Liu
    Bai, Longchuan
    McEachern, Donna
    Yang, Chao-Yie
    Meagher, Jennifer
    Stuckey, Jeanne
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) : 3048 - 3067
  • [30] Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
    Saxena, Nishant
    Katiyar, Shashank P.
    Liu, Ye
    Grover, Abhinav
    Gao, Ran
    Sundar, Durai
    Kaul, Sunil C.
    Wadhwa, Renu
    BIOSCIENCE REPORTS, 2013, 33 : 797 - U315